If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
== Political composition == It was possible for the ILEA to have a majority of Labour members when the GLC had a majority of Conservative members, and this happened from 1970 to 1973 and 1977 to 1981. In addition, most of the important decisions taken by the ILEA were taken by its Education Committee, on which every member sat. The Education Committee could also co-opt members with experience of education, some of them representing the teaching unions. The initial composition of the ILEA in 1964 was 43 Labour members to 9 Conservatives, with one Independent. After the 1967 election the Conservatives won a majority, and Christopher Chataway became Leader. However, Labour won control in 1970 and Ashley Bramall began his long leadership. His term saw the ILEA go over to comprehensive education, and the abolition of school corporal punishment. He retained power despite the Conservative election victory in the 1977 GLC elections. When the Left, under Ken Livingstone, won control of the GLC after the 1981 elections, Bramall lost his position in an internal Labour Party vote, being replaced by Bryn Davies. Livingstone later expressed regret for this decision and expressed his admiration for Bramall's leadership abilities. The remaining years of the ILEA saw a succession of left-wing leaderships, none of which lasted long or established a strong reputation. Frances Morrell, formerly an assistant to Tony Benn, led a feminist ILEA from 1983 to 1987 which threatened to defy its rate-capping in November 1984, before Neil Fletcher took over.
=== Impacts of the underrepresentation of women in certain research and clinical trials === Historically, women were often excluded from clinical trials for reasons such as hormonal variability or concerns about pregnancy-related risks. This exclusion has limited understanding of how certain diseases and treatments affect women. For example, women's cardiovascular diseases—the leading cause of death among women—remain under-researched, and treatment outcomes are often less favorable for women. Other areas with gender data gaps include HIV, some cancers, and the side effects of medication. Due to underrepresentation in trials, women experience more side effects—up to twice as many as men—which has both health and financial consequences, as noted by the French Academy of Medicine in 2016. Drug efficacy may also differ by sex.
== Etiopathogenesis == Recent studies suggest that the pathogenesis of DM is driven by the pathogenic internalization of autoantibodies. Although these antibodies target intracellular proteins, evidence indicates that they can enter different cell types and disrupt the function of their target autoantigens causing inflammation and damage. For example, anti-Mi-2 autoantibodies bind PHD-containing proteins, including component of the NuRD complex, inducing derepression of multiple genes, and in anti-MDA5 dermatomyositis, autoantibodies activate MDA5 directly inducing the activation of type I interferon pathways. The type I interferon pathway is especially prominent in DM and has become a major therapeutic target. Clinical responses to JAK inhibitors, anti-IFNβ therapy, and agents targeting the interferon receptor support the importance of this pathway in disease activity. Conversely, a negative trial of complement inhibition in immune-mediated necrotizing myopathy has challenged earlier models in which complement-mediated muscle injury was considered central to that subtype. The characteristic pathological feature is perifascicular muscle involvement, often accompanied by vasculopathy. Plasma cells are found in close proximity to affected areas with high type I interferon expression and have been observed to externalize immunoglobulin heavy- and light-chain RNA into surrounding muscle cells, suggesting that this may be a potential mechanism for immunoglobulin entry into affected cell types shared across different forms of DM.
Sources: en.wikipedia.org
The suit also alleged that Theranos had misled company directors about its practices concerning laboratory testing and that it had secretly bought lab equipment to run fake demonstrations. On May 1, 2017, Theranos announced that it had reached an undisclosed settlement with Partner Fund Management LP (PFM). Theranos's General Counsel, David Taylor, stated: "Theranos is pleased to have resolved both lawsuits with PFM. Although we are confident that we would have prevailed at trial, resolution of these two cases allows our tender offer to go forward and enables us to return our focus where it belongs, which is on executing our business plans and delivering value for our shareholders." In April 2017, Theranos reached a settlement with CMS agreeing to stay out of the blood-testing business for at least two years in exchange for reduced penalties, and signed a consent decree with Arizona Attorney General Mark Brnovich over violations of the Arizona Consumer Fraud Act. Alleged violations included false advertisement and inaccurate blood testing. Theranos agreed to refund $4.65 million to the state's residents for Theranos blood testing services, providing a refund to every resident who had received a test, regardless of whether the test results were voided or corrected. In August 2017, Theranos announced it had reached a settlement with Walgreens. In December 2017, Fortress Investment Group, a wholly owned company of Softbank Group, loaned $100 million to Theranos for 4% of the company.
The rising interest in chemical biology has led to several journals dedicated to the field. Nature Chemical Biology, created in 2005, and ACS Chemical Biology, created in 2006, are two of the most well-known journals in this field, with impact factors of 14.8 and 4.0 respectively. Chemical Biology is regarded as a distinct field, but many scientists with formal academic education in Biochemistry or Molecular Biology have also contributed to Chemical Biology, showing the overlap between these mentioned fields.
== Side effects == The most frequent side effects, occurring in 20% or more of users, are dry mouth, drowsiness, dizziness, constipation, and weight gain (on average 1.8 kg). Other common side effects are headache problems (amblyopia, blurred vision), tachycardia, increased appetite, tremor, fatigue/asthenia/feeling slowed down, and dyspepsia. A less common side effect of amitriptyline is urinary retention (8.7%). Amitriptyline can increase suicidal thoughts and behavior in people under the age of 24 and the US FDA required a boxed warning to be added to the prescription label. Amitriptyline-associated sexual dysfunction (occurring at a frequency of 6.9%) seems to be mostly confined to male patients with depression and is expressed predominantly as erectile dysfunction and low libido disorder, with lesser frequency of ejaculatory and orgasmic problems. The rate of sexual dysfunction in males treated for indications other than depression and in females is not significantly different from placebo. Liver test abnormalities occur in 10–12% of patients on amitriptyline, but are usually mild, asymptomatic, and transient, with consistently elevated alanine transaminase in 3% of all patients. The increases of the enzymes above the 3-fold threshold of liver toxicity are uncommon, and cases of clinically apparent liver toxicity are rare; nevertheless, amitriptyline is placed in the group of antidepressants with greater risks of hepatic toxicity. Amitriptyline prolongs the QT interval. This prolongation is relatively small at therapeutic doses but becomes severe in overdose.
== Work == Ruhrarbeiter gegen den Faschismus Dokumentation über den Widerstand im Ruhrgebeit 1933–1945, Frankfurt am Main, 1976. Die Reihen fast geschlossen: Beiträge zur Geschichte des Alltags unterm Nationalsozialismus co-edited with Jürgen Reulecke & Adelheid Gräfin zu Castell-Rüdenhausen, Wuppertal: Hammer, 1981. Volksgenossen und Gemeinschaftsfremde: Anpassung, Ausmerze und Aufbegehren unter dem Nationalsozialismus Cologne: Bund Verlag, 1982, translated into English by Richard Deveson as Inside Nazi Germany: Conformity, Opposition and Racism in Everyday Life London: Batsford, 1987 ISBN 0-7134-5217-X. Die Weimarer Republik : Krisenjahre der Klassischen Moderne, Frankfurt am Main: Suhrkamp Verlag, 1987 translated into English as The Weimar Republic: the Crisis of Classical Modernity, New York : Hill and Wang, 1992 ISBN 0-8090-9674-9. “The Genesis of the `Final Solution’ from the Spirit of Science” pages 234-252 from Reevaluating the Third Reich edited by Thomas Childers and Jane Caplan, New York: Holmes & Meier, 1994 ISBN 0-8419-1178-9. The German original was published as "Die Genesis der 'Endlösung' aus dem Geist der Wissenschaft," in Max Webers Diagnose der Moderne, edited by Detlev Peukert (Göttingen: Vandenhoeck & Ruprecht, 1989), pages 102–21, ISBN 3-525-33562-8.
Sources: en.wikipedia.org
== Signs and symptoms == The most common sign of nickel allergy is inflammation of the skin at an area that comes into regular contact with nickel. This often takes the form of a reddened patch of skin with raised bumps (papules) or small blisters (vesicles), and edema. People with chronic dermatitis tend to have dry, scaly, and cracked skin at the site of contact. These sites of inflammation (called "primary eruptions") can occur anywhere on the skin that contacts nickel, but are most common on the hands, face, or anywhere that contacts metal objects such as jewelry or metal clothes buttons. Particularly high levels of nickel exposure can cause irritated patches of skin to appear at other sites on the body (called "secondary eruptions"). These typically occur as blistering rashes on the hands, eyelids, and at the inside of flexing joints (inside the elbow, back of the knee, etc.). Ingestion of nickel may cause a systemic reaction, which can result in generalized inflammation of the skin across the body, small blisters in the hands, irritation inside the flexing joints (flexural eczema), and redness and irritation of both buttocks. Systemic contact dermatitis (SCD) is defined as a dermatitis occurring in an epi-cutaneously contact-sensitized person when exposed to haptens systemically such as orally, per rectum, intravesically, transcutaneously, intrauterinely, intravenously, or by inhalation. The pathophysiology of systemic nickel allergy syndrome (SNAS) is not well understood.
== Further reading == Barrett, Doreen; Bilic, Sanela; Chyung, Yung; Cote, Shaun M.; Iarrobino, Ryan; Kacena, Katherine; et al. (2021). "A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy". Advances in Therapy. 38 (6): 3203–3222. doi:10.1007/s12325-021-01757-z. ISSN 0741-238X. PMC 8189951. PMID 33963971. Crawford, Thomas; Darras, Basil; Day, John; Song, Guochen; Nomikos, George; Place, Amy; et al. (3 May 2022). "Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15-5.005)". Neurology. 98 (18 Supplement) 1859. doi:10.1212/WNL.98.18_supplement.1859. ISSN 0028-3878. Crawford, Thomas; Place, Amy; Barrett, Doreen; Cote, Shaun; Nomikos, George; Song, Guochen; et al. (2021). "Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study". Journal of the Neurological Sciences. 429 118388. doi:10.1016/j.jns.2021.118388. S2CID 238481481. Pratley RE, Denham DS, Trivedi R, Watkins E, Connery L, Barnes J, et al. (July 2026). "Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial". Nature medicine: 2673–2678. doi:10.1038/s41591-026-04440-4. PMC 13375528. PMID 42260100.
== Taxonomy == FishBase recognizes four species in the genus. In addition to these, evidence suggests that a fifth species, A. arapaima, should be recognized (this being the widespread, well-known species, otherwise included in A. gigas).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.